NR3C1 and cancer: Correspondingly, preclinical studies showed that GR activation diminished the efficacy of chemotherapy and apoptosis in triple negative breast cancer xenograft tumors and that systemic treatment with a GR antagonist could reverse the effects of the anti-cancer agents [33,34].